Results 21 to 30 of about 309 (92)

Post-marketing safety of tarlatamab in small cell lung cancer based on FAERS and WHO-VigiAccess with SHAP-based interpretable machine learning analysis of immune-related adverse events [PDF]

Frontiers in Pharmacology
BackgroundTarlatamab is a DLL3-targeted bispecific T-cell engager approved for previously treated extensive-stage small cell lung cancer (ES-SCLC).
Yingyong Ou, Xianxian Zhong, Mei Mei, Xiao Gu, Shanshan Luo, Gaoyu Chen, Xuqin Xie, Desheng Sun   +7 more
doaj   +3 more sources

The characteristics of adverse reactions of three anti-prostate cancer drugs based on Vigiaccess database and bibliometric analysis [PDF]

Frontiers in Pharmacology
BackgroundAndrogen antagonists, including apalutamide, darolutamide, and enzalutamide, play a crucial role in the treatment of prostate cancer.
Jianqing Wang, Liwei Zhang, Wang Jianqing   +2 more
exaly   +4 more sources

Acute Renal Failure in a Patient with Rivaroxaban-Induced Hypersensitivity Syndrome: A Case Report with a Review of the Literature and of Pharmacovigilance Registries

Case Reports in Nephrology, 2020
Direct oral anticoagulants (DOACs) are among the most commonly prescribed medications, and DOAC-associated kidney dysfunction may be a problem that is underrecognized by clinicians. We report on the case of an 82-year-old patient who, two weeks after the
Gisela Marcelino, Ould Maouloud Hemett, Eric Descombes   +2 more
doaj   +2 more sources

Profiles and influencing factors of pulmonary fibrosis associated with biologic and conventional disease-modifying antirheumatic drugs for autoimmune diseases: a disproportionality study based on FAERS and VigiAccess [PDF]

Frontiers in Pharmacology
BackgroundPulmonary fibrosis is a severe and potentially fatal adverse event, and its association with disease-modifying antirheumatic drugs (DMARDs) has raised long-standing concerns. However, systematic investigations on this topic are lacking.
Xinyue Zhang, Xinhui Wu, Cheng Luo, Chun Yang, Nan Jia, Jiayi He, Qian Chen, Fei Wang   +7 more
doaj   +2 more sources

Profiles of neuropsychiatric toxicity associated with different endocrine therapies for breast cancer: a global pharmacovigilance study based on FAERS and VigiAccess [PDF]

Frontiers in Pharmacology
PurposeBreast cancer is the most common malignancy in women. Hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer patients rely on endocrine therapy as their fundamental systemic treatment strategy.
Guoqiang Li, Mengqi Yang, Lei Zhang, Xin Li, Xiaoliang Wu, Feng Peng, Yajie Liu   +6 more
doaj   +2 more sources

Pharmacovigilance evaluation of somatrogon-associated adverse events in real-world databases [PDF]

Endocrine Connections
Background: Somatrogon, a long-acting recombinant human growth hormone, is used in children with growth hormone deficiency. While clinical trials have shown its safety, real-world post-marketing data are limited, and uncommon or delayed adverse events ...
Mengyuan Cai, Qian Guo, Huqiang Dong, Yabo Wang, Zhongyu Han, Ping Xu   +5 more
doaj   +2 more sources

Real‐World Data Analysis of Vascular and Lymphatic Adverse Events Associated With Antitumor Angiogenesis Drugs: A WHO‐VigiAccess Study

Journal of Clinical Pharmacy and Therapeutics
Antiangiogenic therapy plays a critical role in cancer treatment. This study analyzed vascular and lymphatic adverse events linked to four FDA‐approved agents—aflibercept, bevacizumab, olaratumab, and ramucirumab—using WHO‐VigiAccess data. Disproportionality analysis (ROR and PRR) identified drug‐specific risks, focusing on hypertension, hemorrhage ...
Yue Zu, Lingling Dai, Peng Meng
wiley   +3 more sources

Safety profile of ticagrelor: an analysis based on literature and database review [PDF]

BMC Cardiovascular Disorders
Objective Ticagrelor, a reversible P2Y12 receptor antagonist, is widely used in acute coronary syndromes (ACS) for its superior efficacy over clopidogrel.
Renzhu Liu, Lu Xiao, Qingzi Yan, Xiang Liu   +3 more
doaj   +2 more sources

Real-world safety of aliskiren in primary hypertension: A cross-database study. [PDF]

PLoS ONE
Hypertension is one of the main causes of cardiovascular diseases worldwide, affecting over one billion people. Although aliskiren offers a valuable option for inhibiting the renin-angiotensin system, its safety profile in the real world remains ...
Meirong Shan, Qian Guo, Ruofei Li, Ni Li, Yanhua Fu, Huanyu Qi, Ge Zhang, Qian Wang, Xingli Xu, Jinchuan Lai   +9 more
doaj   +2 more sources

Real world pharmacovigilance comparison of viloxazine and dextroamphetamine adverse reaction profiles [PDF]

Scientific Reports
Viloxazine and dextroamphetamine as newly approved drugs for the medical treatment of Attention Deficit Hyperactivity Disorder (ADHD) in recent years give new options for the treating of related disorders, including anxiety, and depression.
Lijun Wang, Qingyang Kong, Yixuan Li
doaj   +2 more sources